

Colin C Collins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/549691/publications.pdf>

Version: 2024-02-01

33
papers

3,634
citations

304743

22
h-index

414414

32
g-index

35
all docs

35
docs citations

35
times ranked

6179
citing authors

#	ARTICLE	IF	CITATIONS
1	Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer. <i>Cells</i> , 2022, 11, 1550.	4.1	0
2	<scp>GRB10</scp> sustains <scp>AR</scp> activity by interacting with <scp>PP2A</scp> in prostate cancer cells. <i>International Journal of Cancer</i> , 2021, 148, 469-480.	5.1	3
3	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 7349.	12.8	51
4	Identification of conserved evolutionary trajectories in tumors. <i>Bioinformatics</i> , 2020, 36, i427-i435.	4.1	9
5	Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression. <i>Oncotmmunology</i> , 2020, 9, 1851950.	4.6	8
6	Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development. <i>Cells</i> , 2020, 9, 1398.	4.1	13
7	Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 3453-3461.	5.1	18
8	Combinatorial Detection of Conserved Alteration Patterns for Identifying Cancer Subnetworks. <i>GigaScience</i> , 2019, 8, .	6.4	9
9	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , 2019, 176, 831-843.e22.	28.9	317
10	BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. <i>Genome Medicine</i> , 2019, 11, 8.	8.2	88
11	Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA. <i>Nucleic Acids Research</i> , 2019, 47, e38-e38.	14.5	17
12	Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target. <i>Cancer Cell International</i> , 2019, 19, 10.	4.1	31
13	Heterochromatin Protein 1 \pm Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 2691-2704.	0.9	48
14	Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. <i>European Urology</i> , 2018, 73, 949-960.	1.9	19
15	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. <i>European Urology</i> , 2018, 73, 524-532.	1.9	60
16	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. <i>GigaScience</i> , 2018, 7, .	6.4	54
17	SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. <i>European Urology</i> , 2017, 71, 68-78.	1.9	136
18	HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology. <i>Genome Research</i> , 2017, 27, 1573-1588.	5.5	78

#	ARTICLE	IF	CITATIONS
19	The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. <i>Cancer Discovery</i> , 2017, 7, 54-71.	9.4	285
20	Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. <i>Genes and Cancer</i> , 2017, 7, 340-354.	1.9	20
21	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. <i>Oncotarget</i> , 2017, 8, 18949-18967.	1.8	47
22	Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. <i>Clinical Epigenetics</i> , 2016, 8, 16.	4.1	55
23	The Proteome of Primary Prostate Cancer. <i>European Urology</i> , 2016, 69, 942-952.	1.9	122
24	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , 2015, 47, 736-745.	21.4	395
25	Polycomb-mediated silencing in neuroendocrine prostate cancer. <i>Clinical Epigenetics</i> , 2015, 7, 40.	4.1	93
26	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. <i>Cell Reports</i> , 2015, 12, 922-936.	6.4	216
27	High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development. <i>Cancer Research</i> , 2014, 74, 1272-1283.	0.9	304
28	Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. <i>Genome Biology</i> , 2014, 15, 426.	8.8	71
29	Lessons from patient-derived xenografts for better in vitro modeling of human cancer. <i>Advanced Drug Delivery Reviews</i> , 2014, 79-80, 222-237.	13.7	146
30	Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient–derived, advanced prostate cancer tissue xenograft model. <i>Molecular Oncology</i> , 2014, 8, 311-322.	4.6	28
31	A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines. <i>PLoS ONE</i> , 2014, 9, e103050.	2.5	7
32	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. <i>Journal of Pathology</i> , 2012, 227, 286-297.	4.5	161
33	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. <i>Cancer Discovery</i> , 2011, 1, 487-495.	9.4	725